Holmium-166 Radioembolization: Current Status and Future Prospective

Stella, Martina; Braat, Arthur J. A. T.; Rooij, Rob van; Jong, Hugo W. A. M. de; Lam, Marnix G. E. H.

doi:10.1007/s00270-022-03187-y

Cited by 39 publications

(32 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TARE is usually performed with Yttrium-90 (90Y) in resin or glass microspheres (although there are ever-increasing reports regarding the effectiveness of Holmium-166 (166Ho) in poly(L-lactic acid) (PLLA) microspheres) [ 95 ]. As opposed to TACE, TARE utilizes local beta radiation to achieve tumor necrosis instead of artery occlusion.…”

Section: Endovascular Treatments and Immuno-oncologymentioning

confidence: 99%

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Posa

Contegiacomo

Ponziani

et al. 2023

IJMS

View full text Add to dashboard Cite

Personalized cancer treatments help to deliver tailored and biologically driven therapies for cancer patients. Interventional oncology techniques are able to treat malignancies in a locoregional fashion, with a variety of mechanisms of action leading to tumor necrosis. Tumor destruction determines a great availability of tumor antigens that can be recognized by the immune system, potentially triggering an immune response. The advent of immunotherapy in cancer care, with the introduction of specific immune checkpoint inhibitors, has led to the investigation of the synergy of these drugs when used in combination with interventional oncology treatments. The aim of this paper is to review the most recent advances in the field of interventional oncology locoregional treatments and their interactions with immunotherapy.

show abstract

Section: Endovascular Treatments and Immuno-oncologymentioning

confidence: 99%

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Posa

Contegiacomo

Ponziani

et al. 2023

IJMS

View full text Add to dashboard Cite

show abstract

“…These Monte Carlo simulations are for now only used in research and development, involving important computer processing resources and time, with software that is not commercialized nor available for routine clinical use. Therefore, the monocompartmental model is recommended using 166 Ho microspheres, targeting a maximum of 60 Gy to the whole liver volume [ 70 ]. Nevertheless, a recent study evaluating post-therapy 166 Ho SPECT/CT dosimetry demonstrated a dose response relationship and a better outcome for patients treated with a tumor absorbed dose of at least 90 Gy (for colorectal metastases).…”

Section: Pre-therapy Imaging With 166 Ho Spect/ctmentioning

confidence: 99%

A Theranostic Approach in SIRT: Value of Pre-Therapy Imaging in Treatment Planning

Dabadie

Walrand

Lhommel

et al. 2022

JCM

View full text Add to dashboard Cite

Selective internal radiation therapy (SIRT) is one of the treatment options for liver tumors. Microspheres labelled with a therapeutic radionuclide (90Y or 166Ho) are injected into the liver artery feeding the tumor(s), usually achieving a high tumor absorbed dose and a high tumor control rate. This treatment adopts a theranostic approach with a mandatory simulation phase, using a surrogate to radioactive microspheres (99mTc-macroaggregated albumin, MAA) or a scout dose of 166Ho microspheres, imaged by SPECT/CT. This pre-therapy imaging aims to evaluate the tumor targeting and detect potential contraindications to SIRT, i.e., digestive extrahepatic uptake or excessive lung shunt. Moreover, the absorbed doses to the tumor(s) and the healthy liver can be estimated and used for planning the therapeutic activity for SIRT optimization. The aim of this review is to evaluate the accuracy of this theranostic approach using pre-therapy imaging for simulating the biodistribution of the microspheres. This review synthesizes the recent publications demonstrating the advantages and limitations of pre-therapy imaging in SIRT, particularly for activity planning.

show abstract

“…Therefore, some theranostic radiopharmaceuticals have been explored in the past to substitute 90 Y-microspheres in liver radioembolization. For example, Holmium-166 ( 166 Ho)-poly-L-lactic acid (PLLA) microsphere has received Conformité Européenne (CE) certification in 2015 under the commercial name QuiremSpheres™ (Quirem BV, Deventer, the Netherlands) [ 7 ]. There are some other potential theranostic radionuclides such as Iodine-131 ( 131 I) and Rhenium-188 ( 188 Re) [ 8 , 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of Therapeutic Efficacy and Imaging Capabilities of 153Sm2O3-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model

et al. 2023

View full text Add to dashboard Cite

Introduction: Neutron-activated samarium-153-oxide-loaded polystyrene ([153Sm]Sm2O3-PS) microspheres has been developed in previous study as a potential theranostic agent for hepatic radioembolization. In this study, the therapeutic efficacy and diagnostic imaging capabilities of the formulation was assessed using liver cancer Sprague-Dawley (SD) rat model. Methods: Twelve male SD rats (150–200 g) that implanted with N1-S1 hepatoma cell line orthotopically were divided into two groups (study versus control) to monitor the tumour growth along 60 days of treatment. The study group received an intra-tumoural injection of approximately 37 MBq of [153Sm]Sm2O3-PS microspheres, while control group received an intra-tumoural injection of 0.1 mL of saline solution. A clinical single photon emission computed tomography/computed tomography (SPECT/CT) system was used to scan the rats at Day 5 post-injection to investigate the diagnostic imaging capabilities of the microspheres. All rats were monitored for change in tumour volume using a portable ultrasound system throughout the study period. Histopathological examination (HPE) was performed after the rats were euthanized at Day 60. Results: At Day 60, no tumour was observed on the ultrasound images of all rats in the study group. In contrast, the tumour volumes in the control group were 24-fold larger compared to baseline. Statistically significant difference was observed in tumour volumes between the study and control groups (p < 0.05). The SPECT/CT images clearly displayed the location of [153Sm]Sm2O3-PS in the liver tumour of all rats at Day 5 post-injection. Additionally, the [153Sm]Sm2O3-PS microspheres was visible on the CT images and this has added to the benefits of 153Sm as a CT contrast agent. The HPE results showed that the [153Sm]Sm2O3-PS microspheres remained concentrated at the injection site with no tumour cells observed in the study group. Conclusions: Neutron-activated [153Sm]Sm2O3-PS microspheres demonstrated excellent therapeutic and diagnostic imaging capabilities for theranostic treatment of liver cancer in a SD rat model. Further studies with different animal and tumour models are planned to validate this finding.

show abstract

Holmium-166 Radioembolization: Current Status and Future Prospective

Cited by 39 publications

References 32 publications

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

Interventional Oncology and Immuno-Oncology: Current Challenges and Future Trends

A Theranostic Approach in SIRT: Value of Pre-Therapy Imaging in Treatment Planning

Evaluation of Therapeutic Efficacy and Imaging Capabilities of 153Sm2O3-Loaded Polystyrene Microspheres for Intra-Tumoural Radionuclide Therapy of Liver Cancer Using Sprague-Dawley Rat Model

Contact Info

Product

Resources

About